Physician profile
Christopher Brown
NPI 1912958935
$2,587.31
in general payments reported to CMS, 2019-2025
25 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $60.08 · 2021: $421 · 2022: $199 · 2023: $521 · 2024: $486 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.94 |
| Education | $293.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $737.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $401.78 | 2019-2025 | Lokelma |
| Opko Pharmaceuticals, LLC | $227.77 | 2019-2024 | Rayaldee |
| Amgen INC. | $143.23 | 2023-2025 | Tavneos |
| Alexion Pharmaceuticals, INC. | $118.51 | 2024 | Soliris, Ultomiris |
| Mallinckrodt Hospital Products INC. | $113.72 | 2022-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $108.55 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.49 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $79.40 | 2019-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $78.94 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $76.64 | 2024-2025 | |
| Novo Nordisk INC | $68.51 | 2025 | Ozempic |
| Vifor Pharma, INC. | $46.80 | 2020-2021 | |
| Genentech USA, INC. | $46.00 | 2025 | Gazyva |
| Travere Therapeutics, INC. | $30.80 | 2024-2025 | Filspari |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $29.63 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $28.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.19 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $20.96 | 2025 | |
| Renalytix Ai, INC. | $20.53 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Grifols USA, LLC | $17.35 | 2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $17.02 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Alnylam Pharmaceuticals INC. | $16.78 | 2021 | |
| Ardelyx, INC. | $15.92 | 2024 | Ibsrela |
| Amag Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.